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Abstract
Introduction: Delirium has a high mortality rate. Understanding predictors of prognosis in patients with
delirium will aid treatment decisions and communication. This study aimed to explore variables associated
with death during an established episode of delirium in palliative care when haloperidol treatment had been
commenced.
Methods: A consecutive cohort of palliative care patients, from 14 centers across four countries, is reported.
The outcome of interest was death within 14 days from commencement of haloperidol treatment for delirium.
Clinicodemographic variables explored were delirium severity, age, gender, primary life limiting illness, body
mass index (BMI), total daily haloperidol dose at baseline (mg), functional status, and comorbidities.
Results: One hundred and sixteen palliative care patients where vital status was known were included in the
analysis; 45% (n = 52) died within 10 days, and 56% (n = 65) died within 14 days. In multivariate analyses no
clinical or demographic variables predicted death, apart from lower BMI in noncancer patients.
Conclusion: This study has shown a very high mortality rate within two weeks of commencing haloperidol for
delirium in palliative care, with no clear clinical predictors for those with a higher chance of dying. Having a
higher BMI offered some benefit in survival, but only in noncancer patients. When delirium occurs in advanced
illness, discussion should be initiated about the gravity of the clinical situation.
Introduction
    Delirium is frequently encountered in palliative care 
populations, with prevalence rates of 13%–42% cited,
and is associated with significant distress for patients, fami-
lies, and health professionals.1,2 Delirium occurrence in
palliative care should inform treatment discussions with pa-
tients and families,2 including the possibility that delirium
may be a specific prelude to death.
Delirium outcomes in older adults have been extensively ex-
plored, and it is associated with accelerated functional and cog-
nitive decline, longer hospital stays, risk of institutionalization,
and higher risk of death.3–11 The National Institute for Health
Care Excellence (NICE) delirium guidelines12 reported an in-
hospital mortality odds ratio (OR) of 2.6 (95% CI 0.7–6.2) and
mortality at one month of 3.0 (95% CI 1.1–8.4) in medical,
surgical, orthopedic, and intensive care, but explicitly excluded
palliative and cancer settings.13–15
Similarly, in palliative care populations, increased mor-
tality associated with delirium has been confirmed.16–19 Three
prognostic scores in advanced illness include delirium as a
predictor of mortality, namely the palliative prognostic index
(PPI), palliative prognostic score (PaP), and In-hospital Mor-
tality Prediction in Advanced Cancer Patients (IMPACT).20–23
In the PPI, presence of delirium at a single time point, without
accounting for duration or severity of delirium, had a sensi-
tivity of 80% and specificity of 85% in predicting survival in
advanced cancer.22 When a delirium diagnosis is added to the
PaP,20 it is an independent predictor of survival in advanced
cancer, with a median survival of 21 days (95% CI 16–27)
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compared to 39 days (95% CI 33–49) for people without de-
lirium, and slightly improves its predictive value.23 More re-
cently, IMPACT was developed to explore utility of clinical
variables to predict mortality during acute palliative care unit
admissions,21 with mortality independently associated with
physician-diagnosed delirium (onDSM-IV-R criteria; OR= 4.3,
95% CI 1.3–14.8; p=0.02).21
Once delirium has occurred, mortality is predicted by ill-
ness severity,24 age, and prior cognitive impairment/demen-
tia in older adults.4 Two studies to date have demonstrated
that shorter survival for palliative patients with delirium is
associated with persistent delirium, severe cognitive im-
pairment related to the delirium episode, both younger and
older age, hypoxemia, and metabolic changes related to or-
gan failure.17,18 In previous studies of patients with cancer,
dementia was only present in 7% of patients with delirium, a
major predictor of higher mortality due to delirium in other
settings.17 The purpose of this study was to explore predictors
of mortality associated with delirium in palliative care.
Methods
This was a secondary analysis of a consecutive prospective
cohort of hospice/palliative care patients prescribed halo-
peridol for delirium as part of routine clinical practice in 14
centers in four countries.25,26 Participating sites had ethical
approval under low or negligible risk research or ethical
waivers.25,26 The National Cancer Institute’s Common Ter-
minology Criteria for Adverse Events (NCI CTCAE)27 was
used to grade delirium severity (Table 1).
Baseline clinical variables were derived from routinely
collected and noninvasive clinical data and included age,
gender, life limiting illness (cancer, noncancer), body mass
index (BMI), daily haloperidol dose at baseline (mg), func-
tional status (Australian-modified Karnofsky Performance
Status scale [AKPS]),28 and comorbidities (Charlson Co-
morbidity Index [CCI] while removing the score for the
primary life-limiting illness).29,30
Death at 14 days from commencing haloperidol was the
primary outcome, given that this was the time period covered
by prospective data collection, encompassing the time frame
for the immediate and short-term benefits and harms of hal-
operidol in treating delirium.
Delirium severity was divided into three groups according
to NCI CTCAE scores: mild (score 1), moderate (score of 2),
and severe (score of 3 or 4, where hospitalization was re-
quired). Differences in continuous demographic attributes
between groups were assessed by analysis of variance or the
Kruskal–Wallis test, depending on whether normality con-
ditions were met. For categorical variables, chi-square tests
were used. Cox proportion hazard regression analysis was
conducted to adjust for potential confounders identified in the
literature that may help to predict death: gender, age, func-
tional status, primary illness, the number of comorbid con-
ditions, BMI, 24-hour haloperidol dose, and baseline
delirium severity. A p-value of less than 0.05 (two-tailed) was
considered statistically significant, and results are presented
as hazard ratios (HR) with 95% confidence intervals. All
analyses were conducted using Stata 13.1 (StataCorp, Texas,
USA).
Results
These patients (n = 119) have been described previously
and had a median age of 75 years (range 34–99) and the
majority (88%) had cancer.25 For this substudy, patients were
stratified by baseline delirium severity (Table 2). Where vital
status was known, at 14 days, 65 of the 116 (56%) patients
had died. Of the patients who died, care was being delivered
in a palliative care unit (n = 21), acute care palliative care
service (n = 9), and community palliative care service
(n = 23), with the remainder of the participants from services
that had both community and inpatient services. The mean
age in the moderate (n = 37; 77 years) and severe delirium
(n = 50; 75 years) categories was older than the mild category
(n = 27; 66 years; p < 0.002).
Severity of delirium, age, gender, haloperidol dose, func-
tional status, or presence of comorbidities was not a predictor
of death after adjusted for the other available confounders
known potentially to influence delirium outcomes (Table 3).
The only finding was a significant interaction between BMI
and primary illness ( p= 0.036). In noncancer patients
(n = 14), higher BMI was associated with decreasing risk of
death (HR = 0.66; (95% CI 0.45–0.97; p= 0.033), but this
association was not seen in majority of the participants who
were cancer patients (n = 105) ( p = 0.62).
Discussion
This study has found that lower BMI was the only factor
predictive of poorer survival for palliative care patients with
delirium receiving treatment with haloperidol, but only in
12% of the sample who had noncancer diagnoses. Our find-
ings also confirm a high immediate mortality rate for deliri-
um,16–18 in a predominantly cancer palliative care population
with delirium receiving haloperidol, consistent with prior
studies.22 Our data have not demonstrated an association with
age, where prior studies have shown contradictory results
with both younger and older age groups seemingly at
risk.4,17,18 Our study chose to include only measures, which
were routinely collected in clinical practice and readily
evaluated at the bedside without invasive investigations. We
cannot make direct comparisons between associations with the
physiological parameters and formal delirium or cognitive
measures used in two prior studies that explored predictors of
mortality in palliative care.17,18 Both studies demonstrated
shorter survival with persisting or irreversible delirium.17,18
The first study explored a cohort of cancer patients with-
out central nervous system involvement (n= 140) and dem-
onstrated a 25% 30-day mortality, with younger age, hypoxemia,
Table 1. National Cancer Institute’s Common
Terminology Criteria for Adverse Events27
Graded Delirium Severity
0 No delirium
1 Mild acute confusional state
2 Moderate and acute confusional state limiting
instrumental activities of daily living
3 Severe and acute confusional state limiting self-care
activities of daily living with hospitalization
indicated
4 Life-threatening consequences, threats of self-harm or








and organ impairment (defined as increased serum urea ni-
trogen levels and increased serum alkaline phosphatase)
predictive of the patients who were more likely to die.18 By
contrast, predictors of mortality in a consecutive cohort of
palliative care inpatients (n = 121) who were followed until
recovery or death included the following: severe cognitive
changes due to the delirium (on Cognitive Test for Delirium),
increasing age, and organ failure (on Delirium Etiology
Checklist).17 In the second study, only 13% had prior cog-
nitive impairment, a major predictor of higher mortality due
to delirium in other settings.17
With a median survival of less than two weeks, the real
challenge for clinical practice is what conversations with
families the diagnosis of delirium should generate. These
findings suggest that delirium occurrence by itself should
prompt open discussions with the person and his/her family
about the likely prognosis associated with delirium in the
context of advanced disease, as studies to date have not de-
fined any consistent clinicodemographic factors that predict
risk of death.
The limitations of this study include lack of formal mea-
surement of prior cognitive impairment and liver and renal
function not routinely measured in the participating services,
restricting comparisons with predictors of mortality used in
other studies. The participants predominantly had cancer,
limiting generalizability to noncancer patients; and almost
half of the participants were in the inpatient setting, which
may reflect a group who were sicker or had more complex
medical problems. Delirium and its severity were assessed by
clinicians, and no specific delirium severity scale or method
was used to diagnose delirium; however, the grading cate-
gories utilized have face validity, reflecting the clinical issues
that are deemed serious, namely functional decline, hospi-
talization, and patient safety. It is possible that hypoactive
delirium, the more prevalent subtype in palliative care with
poorer outcomes, was underrepresented, either because pa-
tients did not present with symptoms deemed to require
treatment with haloperidol or the clinician did not utilize
comprehensive assessments methods to detect this subtype of
delirium that is more subtle in presentation.31–33
The predictors of survival may differ in those with delir-
ium not treated with haloperidol. In this study, survival time
was determined from the time of commencement of halo-
peridol, and there may be other factors influencing when such
treatment is started after delirium occurs. Antipsychotic
treatment has been demonstrated in other populations to be
associated with increased mortality.34 The delirium subtype
or phenomenology, which may motivate clinicians to treat
delirium with antipsychotics, has been associated with dif-
fering mortality outcomes.35 Equally the choice of other
antipsychotics other than haloperidol may be related to spe-
cific clinical scenarios with different mortality, for example,
refractory delirium in the imminently dying patient.
Ultimately, delirium in advanced disease carries a very
poor prognosis. The current work needs to be expanded to a
much larger prospective cohort and consent participants to
measure physiological variables and assess delirium phe-
nomenology in more detail, to better understand which pa-
tient or treatment characteristics contribute most to poorer
outcomes and to serve as a guide for clinical conversations.
Evaluation of potential preventative interventions to reduce
the incidence of delirium in this population and assess impact
on survival is also urgently needed.
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